NeuroScientific Biopharmaceuticals Limited Overview
NeuroScientific Biopharmaceuticals is a Perth-based, ASX-listed clinical-stage biotechnology company that, in June 2025, executed a decisive pivot from neuro-peptide drug discovery to allogeneic cell therapy. Through its acquisition of Isopogen WA Ltd, it now owns StemSmart™, a patented manufacturing process for bone-marrow-derived mesenchymal stromal/stem cells (MSCs) originally developed at Royal Perth Hospital, which it is positioning against treatment-refractory and fistulising Crohn's disease — an indication where the leading approved cell therapy in Europe (Takeda's Alofisel) has been withdrawn and biologic failure is common. Real-world data from a Therapeutic Goods Administration Special Access Scheme cohort (4 of 5 patients achieving a protocol-defined clinical response, no serious adverse events) and a historic 18-patient Phase 2 study underpin plans for two Phase 2 trials in Australia and the US, with initiation targeted by end-CY2026. Its legacy peptide EmtinB™ has been fully impaired and is being offered for out-licensing. The investment case is binary, capital-constrained and milestone-driven.
Company's own description. In its FY2026 Annual Report, the company describes its principal activity as research and development of biomedical products aimed at neurodegenerative conditions and immune-mediated inflammatory diseases. In its 2026 ASX releases, NSB characterises itself as a biotechnology company developing novel therapeutics for immune-mediated inflammatory disorders, centred on modulating pathological immune responses in chronic and degenerative conditions where existing therapies have limited efficacy or durability, with an aspiration toward first-in-class or best-in-class biologics (ASX announcement, 13 August 2026).
Independent characterisation. NSB is, in substance, a single-asset cell-therapy development company. Its economic value rests almost entirely on the StemSmart™ MSC platform, carried on balance sheet at A$10.27M (FY2026, Note 10) against total assets of A$15.18M. The company does not manufacture in-house; it has outsourced GMP production to Q-Gen Cell Therapeutics (a QIMR Berghofer-affiliated contract manufacturer in Brisbane) and clinical execution to Southern Star Research (an Australian CRO). Its operating model is therefore "virtual": a small executive team, an advisory board, and contracted service providers coordinated from a Perth office.
Business model. NSB's model is a classic development-and-partner biotech model. Management's own incentive design reveals the intended exit route: the CEO's 1.5 million performance rights vest only on execution of a definitive third-party development and/or commercialisation agreement for the MSC therapy with combined upfront and milestone value of at least US$150 million (FY2026 Annual Report, Remuneration Report). Analyst commentary on the June 2026 quarterly similarly noted the US IND-enabled Phase 2 is designed to attract global partners for Phase 3 development (Kalkine summary of the 28 July 2026 quarterly). NSB is therefore best understood as building a de-risked clinical data package for licensing or sale rather than a fully integrated commercial pharmaceutical company.
Revenue model.
Royalty obligations (outbound). East Metropolitan Health Service (EMHS) is entitled to a 4% royalty on future net sales derived from the MSC technology, and to acquire MSC cells from Isopogen at cost for public patients in the WA public health system (FY2026 Annual Report, Note 20; June 2025 Quarterly Activity Report). The University of Tasmania retains an equity-based milestone entitlement of A$250,000 on EmtinB (Milestone 3: IND or equivalent regulatory acceptance).
Value-chain position. NSB sits at the discovery-to-clinical-development stage. Upstream inputs (donor bone marrow, GMP manufacturing, cleanroom capacity) are contracted; downstream activities (Phase 3, regulatory approval, commercialisation, reimbursement) are intended to be partnered.
Customer types and end-markets. NSB has no customers. Its prospective end-market is gastroenterology — specifically adults with Crohn's disease who have failed or are intolerant to approved biologics and small molecules (refractory luminal Crohn's), and patients with perianal fistulising Crohn's disease. Previously studied secondary indications include steroid-refractory graft-versus-host disease (GVHD) and renal transplantation. The legacy EmtinB asset targeted ophthalmology (advanced glaucoma) and neurology (multiple sclerosis, Alzheimer's disease).
Strategy
Stated strategy (paraphrased from FY2026 Annual Report and 2026 ASX releases). Management's strategic themes are: (1) focus resources exclusively on StemSmart™ in immune-mediated inflammatory diseases with large treatment-resistant populations; (2) lead with refractory and fistulising Crohn's disease; (3) secure GMP-compliant, scalable manufacturing through Q-Gen; (4) run a US IND-enabled Phase 2 to generate partner-grade data; (5) monetise non-core EmtinB via out-licensing while preserving upside.
Strategic initiatives — last 24 months.
Medium-term financial targets / guidance. None. Management guides only qualitatively that net losses will continue as clinical development and GMP manufacturing progress (FY2026 Annual Report).
Products & Services
NSB has no marketed products. Its portfolio consists of development-stage assets, catalogued below asset by asset.
StemSmart™ Mesenchymal Stromal/Stem Cell Platform (lead asset)
| Attribute | Detail |
|---|---|
| Modality | Allogeneic (donor-derived) bone marrow-sourced MSCs |
| Technology | Patented manufacturing process developed at Royal Perth Hospital, designed to enhance therapeutic activity and clinical response and to modulate pathological immune responses (ASX announcement, 13 August 2026) |
| Mechanism (as described by company) | Anti-inflammatory and immunomodulatory activity, dampening inflammation, moderating immune responses and supporting tissue repair (company materials as reported by Biotech Daily, May 2025) |
| Origin | Developed 2007; IP registered to Dr Marian Sturm and Isopogen; acquired by NSB 27 June 2025 |
| Accounting carrying value | A$10,270,298 (cost A$11,554,085 less amortisation A$1,283,787), 9-year useful life (FY2026, Note 10) |
| Manufacturing | Transfer from Cell and Tissue Therapies WA (Royal Perth Hospital) to Q-Gen Cell Therapeutics in progress; engineering runs underway ahead of a TGA audit scheduled October 2026; clinical manufacture targeted early CY2027 (FY2026 Annual Report) |
| Pricing model | Not applicable (pre-commercial) |
| Royalty burden | 4% of net sales to EMHS |
| Program | Indication | Stage | Key data / plan | Source |
|---|---|---|---|---|
| SAS Category B program | Fistulising Crohn's disease (patients who exhausted approved therapies) | Real-world compassionate use, completed initial cohort | 5 patients treated; all improved; 4 of 5 achieved protocol-defined "Clinical Response" (over 50% fistula opening closure or over 50% reduction in discharge); no serious adverse events | FY2026 Annual Report; ASX 26 May 2026 |
| Phase 2 (planned) | Refractory (treatment-resistant) Crohn's disease | Pre-IND meeting scheduled 31 Aug 2026; CRO appointed 1 Oct 2026; IND submission targeted late CY2026; initiation targeted end-CY2026 | Australia and US sites | ASX 13 Aug 2026; ASX 1 Oct 2026 |
| Phase 2 (planned) | Fistulising Crohn's disease | Planning | Second of two planned Phase 2 programs | FY2026 Annual Report |
| Historic Phase 2 (Isopogen) | Refractory Crohn's disease | Completed pre-acquisition | 18 patients; 78% response rate cited by company | FY2026 Annual Report; ASX 16 Apr 2025 |
| Historic Phase 1 (Isopogen) | Steroid-refractory GVHD in adults | Completed pre-acquisition | Supportive safety/activity data cited | ASX 27 Jun 2025 |
| Historic studies | Renal transplantation | Completed pre-acquisition | Company described as promising | ASX 11 Nov 2025 |
StemSmart indication-level pipeline.
Target customer. Gastroenterologists and inflammatory bowel disease centres treating refractory and fistulising Crohn's patients; ultimately a licensing partner.
Addressable market (company-cited). Global Crohn's disease market US$13.8 billion by 2026 (ASX announcements, June–July 2025); a figure of US$13 billion is used in the 13 January 2026 release — the discrepancy reflects differing third-party market reports cited.
EmtinB™ (legacy asset — out-licensing)
| Attribute | Detail |
|---|---|
| Modality | Synthetic peptide modelled on an active domain of human metallothionein-IIA; binds LDLR-family receptors to activate neuroprotective and neuroregenerative signalling |
| Indications pursued | Advanced glaucoma (intravitreal), multiple sclerosis, Alzheimer's disease |
| Stage reached | IND-enabling; GLP toxicology complete (Jul 2023); FDA pre-IND meeting for glaucoma completed (FY2024); never dosed in humans |
| Licence | Exclusive licence (UTAS); cost A$775,000; fully impaired at 30 June 2026 (impairment A$210,928) |
| Strategic status | Board decided in FY2026 not to continue independent development; pursuing out-licensing/partnering |
Other Emtin peptides
| Asset | Description | Status |
|---|---|---|
| EmtinAc | Emtin family peptide reported to show similar therapeutic potential to EmtinB | Preclinical; no recent disclosure |
| EmtinAn | As above | Preclinical; no recent disclosure |
| EmtinBn | As above | Preclinical; no recent disclosure |
Financial Narrative
All figures A$ millions unless stated. Source: Five-year summary in FY2026 Annual Report Remuneration Report (total income, EBITDA, EBIT, net result, EPS, share price); FY2026 and FY2025 Annual Report financial statements; FY2022–FY2024 balance sheet and cash flow items from S&P Global Market Intelligence data (via StockAnalysis), cross-checked to annual report balances where available. Blank cells = not meaningful or not publicly disclosed.
Income statement
Margins. Gross, operating, EBITDA and net margins are not meaningful because NSB has no operating revenue. Revenue CAGR: not applicable.
Ratios (analyst calculations on year-end balances)
ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful for a debt-free, pre-revenue company.
Commentary
FY2022 — peak EmtinB spend. The A$10.4M loss in FY2022 reflects the most intensive phase of EmtinB preclinical and CMC work (S&P data attribute A$7.22M to R&D) and A$1.35M of share-based payments. Accounts payable of A$2.17M at year-end show the scale of contracted work outstanding.
FY2023–FY2024 — retrenchment and tax-refund income. Total income of A$5.06M in FY2023 and A$2.39M in FY2024 consisted largely of R&D Tax Incentive refunds relating to the heavy FY2022 spend, which — combined with sharply lower activity — produced a near break-even FY2023 and the company's only profit (A$0.324M) in FY2024. The FY2024 Annual Report states explicitly that the profit mainly reflected the R&D tax incentive. This was not an operational inflection; it was a lagged cash rebate on prior-year spending during a period of strategic drift.
FY2025 — transformational deal year. The loss of A$1.85M was modest in cash terms (operating outflow A$1.13M), but A$0.80M of it was non-cash director/related-party option expense. The balance sheet tripled to A$16.96M as the Isopogen acquisition added A$9.27M of intangibles (funded by 85.7M consideration shares at A$0.08 and 57.1M performance shares initially recognised at 50% probability), while a A$3.5M placement at A$0.035 lifted cash to A$7.27M.
FY2026 — first full year as a cell-therapy company. The loss widened 154% to A$4.69M. Roughly A$1.58M of the increase is non-cash: StemSmart amortisation commenced (A$1.28M) and the EmtinB licence was written off (A$0.21M). Cash costs rose genuinely too: employee costs nearly quadrupled to A$1.01M with the appointment of a CEO, CSO and CMO, and research consultants rose eight-fold to A$1.08M as tech transfer and trial preparation began. Operating cash burn of A$2.78M was partly cushioned by a A$0.40M R&D incentive refund. Quarterly burn has accelerated through the year — A$0.53M in the December 2025 quarter versus A$1.055M in the June 2026 quarter (Appendix 4C reports) — and will rise further when Phase 2 enrolment and GMP batch production begin. A notable accounting feature is the performance-share probability reassessment: when the SAS milestone was met in May 2026, the probability on the Isopogen performance shares was lifted from 50% to 100%, adding A$2.29M to the StemSmart intangible cost base (Note 14), which in turn increases future amortisation.
Balance-sheet quality. Tangible book value is only A$4.54M; 68% of total assets is a single acquired intangible. Cash and term deposits of A$4.63M against a run-rate quarterly burn of about A$1.0–1.1M imply roughly four quarters of funding before trial-related step-ups — the directors nonetheless state funding is sufficient for at least twelve months from 25 August 2026 (FY2026 Annual Report, going concern note).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products | Status |
|---|---|---|---|
Research & development (Australia) | All activities of the group | StemSmart™ MSC platform; EmtinB™ (out-licensing) | Pre-revenue |
Results by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
R&D segment total income incl. interest and R&D incentive (AUD Mn) | 2.391 | 0.166 | 0.629 |
R&D segment pre-tax result (AUD Mn) | 0.324 | -1.846 | -4.693 |
Share of group total income (%) | 100 | 100 | 100 |
Group Entities
| Entity | Role | Ownership |
|---|---|---|
NeuroScientific Biopharmaceuticals Limited | ASX-listed parent; holds EmtinB licence | — |
Isopogen WA Pty Ltd (converted from Ltd in FY2026) | Holds or has the right to exploit StemSmart™ IP | 100% |
Isopogen Pty Ltd | Group entity | 100% |
Isopogen Australia Pty Ltd | Group entity | 100% |
Isopogen Australia Opco Pty Ltd | Operating entity; counterparty to Q-Gen manufacturing contract | 100% |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Total income incl. interest and R&D incentive (AUD Mn) | 0.068 | 5.060 | 2.391 | 0.166 | 0.629 |
EBITDA (AUD Mn) | -10.370 | -1.011 | 0.416 | -1.753 | -3.308 |
EBIT / operating result (AUD Mn) | -10.435 | -1.069 | 0.324 | -1.846 | -4.692 |
Pre-tax income (AUD Mn) | -10.435 | -1.069 | 0.324 | -1.846 | -4.693 |
Net income (AUD Mn) | -10.435 | -1.069 | 0.324 | -1.846 | -4.693 |
EPS basic (AUD cents) | -7.27 | -0.74 | 0.22 | -1.26 | -1.39 |
EPS diluted (AUD cents) | -7.27 | -0.74 | 0.22 | -1.26 | -1.39 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Weighted avg shares basic (M) | — | — | — | 146.66 | 337.27 |
Expense line (AUD)
| Expense line (AUD) | FY2025 | FY2026 |
|---|---|---|
Administration | 228,724 | 251,808 |
Consultants – professional | 309,557 | 531,247 |
Consultants – research | 128,730 | 1,083,616 |
Conferences and travel | 0 | 98,018 |
Insurance | 129,234 | 131,106 |
Patent costs | -473 | 144,382 |
Employee expenses | 272,576 | 1,012,534 |
Management fees | 50,000 | 50,000 |
Share-based payments | 798,000 | 421,028 |
Depreciation | 5,590 | 13,249 |
Amortisation | 87,190 | 1,370,975 |
Impairment (EmtinB licence) | 0 | 210,928 |
Finance costs | 2,463 | 3,671 |
Balance Sheet and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 7.74 | 5.29 | 5.44 | 16.96 | 15.18 |
Cash and equivalents (AUD Mn) | 7.22 | 4.91 | 4.95 | 7.27 | 2.63 |
Term deposits (AUD Mn) | 0 | 0 | 0 | 0 | 2.00 |
Cash plus term deposits (AUD Mn) | 7.22 | 4.91 | 4.95 | 7.27 | 4.63 |
Short-term debt incl. leases (AUD Mn) | 0 | 0 | 0 | 0 | 0.048 |
Long-term debt incl. leases (AUD Mn) | 0 | 0 | 0 | 0 | 0.039 |
Net cash (AUD Mn) | 7.22 | 4.91 | 4.95 | 7.27 | 4.54 |
Total equity (AUD Mn) | 5.52 | 4.69 | 5.35 | 16.81 | 14.81 |
Goodwill (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Intangible assets (AUD Mn) | 0.32 | 0.27 | 0.39 | 9.57 | 10.27 |
Working capital (AUD Mn) | 5.18 | 4.41 | 4.96 | 7.25 | 4.46 |
Total liabilities (AUD Mn) | 2.22 | 0.60 | 0.09 | 0.15 | 0.37 |
Shares outstanding (M) | 143.47 | 143.47 | 144.60 | 332.58 | 389.72 |
NTA per share (AUD cents) | — | — | — | 2.22 | 1.26 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -6.94 | -2.30 | 0.04 | -1.13 | -2.78 |
Capex (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (AUD Mn) | -6.95 | -2.30 | 0.04 | -1.13 | -2.78 |
Equity raised (AUD Mn) | 0 | 0 | 0 | 3.50 | 0 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
R&D tax incentive received in operating cash (AUD Mn) | — | — | — | 0 | 0.403 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on ending equity (%) | -189.0 | -22.8 | 6.1 | -11.0 | -31.7 |
ROA on ending assets (%) | -134.8 | -20.2 | 6.0 | -10.9 | -30.9 |
Current ratio (x) | 3.33 | 8.35 | 56.0 | 49.6 | 14.3 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0.006 |
Region Assets & Liabilities
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia revenue (AUD Mn) | 0 | 0 | 0 |
Americas revenue (AUD Mn) | 0 | 0 | 0 |
EMEA revenue (AUD Mn) | 0 | 0 | 0 |
APAC ex-Australia revenue (AUD Mn) | 0 | 0 | 0 |
Australia non-current assets (AUD Mn) | 0.39 | 9.57 | 10.39 |
Share Price and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.18 | 0.08 | 0.04 | 0.087 | 0.059 |
Shares outstanding at 30 June (M) | 143.47 | 143.47 | 144.60 | 332.58 | 389.72 |
Market capitalisation at 30 June (AUD Mn) | 25.8 | 11.5 | 5.8 | 28.9 | 23.0 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Valuation Multiples
| Multiple | NSB | Comment |
|---|---|---|
Market capitalisation | approx. A$22.6M | 389.72M x A$0.058 |
Enterprise value | approx. A$18.1M | Less net cash A$4.54M (30 Jun 2026) |
P/B | approx. 1.5x | Book equity A$14.81M |
P/Tangible book | approx. 5.0x | Tangible book A$4.54M |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | No broker coverage identified; not publicly available |
Dividend policy | No dividends ever paid; none expected |
Buyback authorisation | None (FY2026 AR Note 13) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No borrowings; lease liabilities A$48,311 due within 1 year and A$38,728 in 1–2 years |
Options on issue (date of FY2026 report) | 250,000 at A$0.40 (exp. Jun 2027); 40,000,000 at A$0.07 (exp. Jun 2028); 1,500,000 at A$0.15 and 1,500,000 at A$0.25 (exp. Sep 2028) — 43.25M total |
Performance rights | 1,500,000 (CEO) |
Fully diluted shares | approx. 434.5M |
Analyst Conclusions
Management guidance. No financial guidance. Operational targets: TGA audit of Q-Gen in October 2026; IND submission by late CY2026; initiation of Phase 2 trials by end CY2026; clinical manufacturing for trials in early CY2027; continued losses expected (FY2026 Annual Report; ASX 13 Aug 2026; ASX 1 Oct 2026).
Consensus growth expectations. None available (no sell-side coverage).
Bull case
-
Data that already looks unusually good. Responses in 4 of 5 heavily pre-treated fistulising patients, alongside a 78% response rate in an earlier 18-patient study, suggest StemSmart may outperform first-generation MSC products — if replicated, this is partnerable.
-
A cleared field in fistulising Crohn's. With Alofisel withdrawn in Europe, a credible bone-marrow MSC with US IND data could become the leading cell-therapy candidate in this niche.
-
Asymmetric valuation. An enterprise value of roughly A$18M for a Phase 2-ready asset, a management team incentivised toward a US$150M+ deal, and a zero-book EmtinB option offer substantial upside relative to downside if milestones land.
Bear case
-
Funding gap. A$4.63M cash and a quarterly burn already above A$1M, before two Phase 2 trials and GMP batches, make a dilutive raise at or near depressed prices highly likely in the next 12 months.
-
Data quality. Small, uncontrolled, single-centre datasets in a field with a history of Phase 3 failures may not survive a randomised design; the market's reaction (share price roughly halved since January 2026 despite good news) suggests scepticism.
-
Execution and comparability. A manufacturing transfer from a hospital lab to a CMO, a pending TGA audit and FDA expectations on potency assays create meaningful scope for delay, with a 4% royalty and a seemingly short patent life eroding the eventual economics.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Disclosure of FDA pre-IND meeting outcome | Overdue / any time | Trial design clarity and US pathway |
| TGA audit outcome for Q-Gen | Oct 2026 onward | Gates clinical supply |
| September 2026 quarterly / Appendix 4C | Late Oct 2026 | Burn rate and cash |
| AGM | Likely Nov 2026 | Placement capacity resolutions, board renewal |
| IND submission and FDA clearance | Late CY2026 / early CY2027 | US enrolment |
| First patient dosed in Phase 2 | Targeted end CY2026; clinical supply early CY2027 | Execution credibility |
| Capital raise | Likely within 12 months | Dilution and price |
| EmtinB out-licence | Undated | Non-dilutive upside |
| Escrow releases | Ongoing | Supply overhang |
Concluding analyst verdict
NeuroScientific Biopharmaceuticals is no longer the company its name implies. Since June 2025 it has been a single-asset cell-therapy developer whose fortunes rest on whether StemSmart™, a bone-marrow MSC product refined at Royal Perth Hospital, can reproduce in a controlled, multi-centre Phase 2 what it has shown in small, uncontrolled settings. The early evidence is genuinely encouraging: four of five refractory fistulising Crohn's patients responding without serious adverse events is a striking result in a population that has exhausted approved therapy, and it aligns with the 78% response rate reported in Isopogen's earlier 18-patient study. The strategic logic is also coherent. Takeda's withdrawal of Alofisel in Europe has left a visible gap, the FDA has now approved an allogeneic MSC product, and management has wisely chosen a partner-oriented model with outsourced manufacturing and clinical execution.
The problem is capital, not concept. With A$4.63M in cash and term deposits, a June-quarter burn of A$1.06M and two Phase 2 trials plus GMP manufacturing still to be funded, NSB will almost certainly need to raise equity — likely before the most value-accretive data are available. The share-price trajectory since January 2026 suggests the market is pricing this dilution in. Governance is lean, the asset is encumbered by a 4% royalty, and the amortisation schedule hints at a relatively short patent runway.
On balance, NSB is a high-risk, binary, speculative development-stage holding. The near-term value drivers are procedural but important: disclosure of FDA pre-IND feedback, a clean TGA audit of Q-Gen, IND clearance and first-patient dosing. Successful delivery of all four within roughly six months, followed by a raise on acceptable terms, would materially de-risk the story; slippage on any of them, combined with a weak market for micro-cap biotech, would likely force financing at punitive levels. Until the controlled data arrive, conviction should remain low and position sizing small.
Source list (primary): NSB FY2026 Annual Report and Appendix 4E (25 Aug 2026); FY2025 Annual Report (28 Aug 2025); FY2024 Annual Report (29 Aug 2024); FY2023 Annual Report (25 Aug 2023); FY2022 Annual Report (30 Aug 2022); FY2020 Annual Report (28 Aug 2020); ASX announcements 27 Jun 2025, 23 Jul 2025, 31 Jul 2025, 30 Oct 2025, 30 Jan 2026, 28 Jul 2026, 13 Aug 2026, 1 Oct 2026. Secondary: StockAnalysis (S&P Global Market Intelligence data); Morningstar Australia; Market Index; InvestSMART announcement summaries; StockLight; Quartr event summaries; Stockhead (Dr Boreham's Crucible, May 2025; 2019 special report); Biotech Daily (3 Jul 2019; 16 May 2025); Biotech Dispatch; Business News WA; Kalkine Media; Medianet.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education | Shares held | Options held |
|---|---|---|---|---|---|---|
Robert McKenzie | Non-Executive Chairman | 27 Jun 2025 | Lawyer, over 45 years in corporate/commercial transactions, restructuring and disputes; former partner Clayton Utz (head of reconstruction and insolvency) and Jackson McDonald; Chair of the Perron Institute; director and risk committee chair at Keystart; former Takeovers Panel member | LL.B, B.Juris, FAICD, RITF | 9,635,792 | 5,000,000 |
Paul Fry | Non-Executive Director; also part-time Commercial Officer | 27 Jun 2025 | Former partner of EY and PwC in Australia and Canada; capital markets, governance and transactions | BBus | 22,471,602 | 5,000,000 |
Clarke Barlow | Non-Executive Director | 5 Dec 2023 | Financial adviser and capital markets specialist, over 20 years in Australia and UK; former NED Tryptamine Therapeutics (ASX:TYP) | BCom, MAICD | Nil | 1,000,000 |
Dr Anton Uvarov | Non-Executive Director | 6 Sep 2017 | Healthcare equity analyst; formerly Citigroup Global Markets NY biotech team; Executive Director BlinkLab (ASX:BB1); NED Patrys (ASX:PAB) | PhD, MBA | 5,000,000 | 1,000,000 |
Executive Leadership Team
| Name | Title | Appointed | Background | Terms |
|---|---|---|---|---|
Nathan Smith | Chief Executive Officer | 28 Jul 2025 | Cell and gene therapy executive; senior roles including Cell Therapies Pty Ltd and GlaxoSmithKline (USA); GMP manufacturing and scale-up expertise | A$250,000 + super; 3M options; 1.5M performance rights |
Dr Marian Sturm | Chief Scientific Officer | 23 Jul 2025 | Inventor of StemSmart; long-time Royal Perth Hospital/EMHS cell therapy scientist; inaugural member of TGA advisory committee on biologics; largest individual shareholder | A$175,000 pro rata at 0.8 FTE |
Dr Catherine Cole | Chief Medical Officer | 24 Jul 2025 | Former Head of Haematology and Oncology at Princess Margaret Hospital and Perth Children's Hospital; Director of Haematopoietic Stem Cell Transplantation | A$500,000 pro rata at 0.2 FTE |
Chris Achurch | Company Secretary | — | Company secretary to multiple ASX companies | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Salary/fees | Superannuation | Bonus (STI) | Share-based | Total |
|---|---|---|---|---|---|
Robert McKenzie | 80,000 | 9,600 | 0 | 0 | 89,600 |
Paul Fry | 154,747 | 18,570 | 0 | 0 | 173,317 |
Clarke Barlow | 55,000 | 6,600 | 0 | 0 | 61,600 |
Anton Uvarov | 50,000 | 0 | 0 | 0 | 50,000 |
Nathan Smith | 238,913 | 27,964 | 0 | 421,028 | 687,905 |
Marian Sturm | 144,515 | 16,950 | 0 | 0 | 161,465 |
Catherine Cole | 102,614 | 11,500 | 0 | 0 | 114,114 |
Total KMP | 825,789 | 91,184 | 0 | 421,028 | 1,338,001 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
FY2024 | Dougal Thring (COO) resigned; Dr Tony Keating appointed Executive Director | EmtinB FDA engagement phase |
27 Jun 2025 | Chris Ntoumenopoulos (Chair) and Tony Keating resigned; McKenzie and Fry appointed | Isopogen completion |
21 Jun 2026 | 5M director options lapsed (A$1.27M reserve transferred) | Legacy options expiry |
Jul 2025 | CEO, CSO, CMO appointed | Build-out of cell therapy team |
Competitive Landscape
Key Competitors
| Competitor | Segment | Relevant product / approach | Relative positioning vs NSB |
|---|---|---|---|
Takeda | Fistulising Crohn's cell therapy; biologics | Alofisel (darvadstrocel, adipose MSC) — withdrawn in EU after confirmatory trial failure; Entyvio (vedolizumab) | Validated the indication then retreated, leaving a gap; also dominant biologic incumbent |
Mesoblast (ASX: MSB) | Allogeneic MSC therapy | Ryoncil (remestemcel-L) approved by FDA for paediatric steroid-refractory acute GVHD | Closest listed Australian MSC peer; far larger, with an approved product and manufacturing scale |
Cynata Therapeutics (ASX: CYP) | iPSC-derived MSCs | Cymerus platform; GVHD and other inflammatory indications | Alternative MSC sourcing technology; similar micro/small-cap ASX peer |
AbbVie | Crohn's biologics/small molecules | Humira, Skyrizi, Rinvoq | Standard-of-care incumbents that define the "refractory" population NSB targets |
Johnson & Johnson | Crohn's biologics | Stelara, Tremfya | Incumbent; potential partner |
Eli Lilly | Crohn's biologics | Omvoh (mirikizumab) | Incumbent; potential partner |
Pfizer | IBD small molecules | Velsipity (UC), pipeline | Adjacent |
Pluri (formerly Pluristem) | Placental cell therapy | Inflammatory/regenerative programs | Cell-therapy peer |
Longeveron | Allogeneic MSC | Laromestrocel (cardiac, ageing indications) | MSC peer, different indications |
Academic/hospital MSC programs (e.g., Leiden bone-marrow MSC for perianal fistula) | Fistulising Crohn's | Local injection MSC studies | Scientific competition for the same niche |
Peer Comparison FY2026
| Metric | NSB (FY2026) | Mesoblast | Cynata | Takeda |
|---|---|---|---|---|
Revenue | A$0 | — | — | — |
Approved MSC product | — | Ryoncil (US) | — | Alofisel (withdrawn EU) |
Stage in Crohn's | Phase 2 planned | Not a stated focus | Not a stated focus | Exited cell therapy indication in EU |
Recent Developments
--



